RCAP
SLNO

Resolute Capital Asset Partners’s Soleno Therapeutics SLNO Stock Holding History

Resolute Capital Asset Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,402
Closed -$3.05M – 63
2025
Q2 		$3.05M Sell
36,402
-3,598
-9% -$269K 1.59% 23
2025
Q1 		$2.86M Buy
+40,000
New +$1.95M 1.61% 23

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Resolute Capital Asset Partners's SLNO Position: Q3 2025 in Review

Resolute Capital Asset Partners sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 36,402 shares — an estimated $3.05M sold.

Resolute Capital Asset Partners first reported a position in SLNO in Q1 2025 and held it in 2 quarters. The position peaked at $3.05M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Resolute Capital Asset Partners reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 36,402 Soleno Therapeutics shares in Q3 2025, an estimated $3.05M.
  • Resolute Capital Asset Partners first reported a position in Soleno Therapeutics in Q1 2025 and held it in 2 quarters.
  • Resolute Capital Asset Partners's Soleno Therapeutics position peaked at $3.05M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Resolute Capital Asset Partners's 13F filing for Q3 2025, filed 14 Nov 2025.